Overview

West Nile virus (WNV) is an RNA virus in the family Flaviviridae, genus Flavivirus. It causes a range of illness collectively known as West Nile virus disease. WNV naturally cycles between birds and mosquitoes and can incidentally infect mammals, including humans and horses. Most human infections are mild or asymptomatic, but the virus can occasionally produce serious neurologic disease.

Characteristics and transmission

WNV is an enveloped, single-stranded positive-sense RNA virus. The natural transmission cycle involves ornithophilic mosquitoes that acquire the virus when feeding on infected birds; infected mosquitoes then spread the virus to additional birds and to incidental hosts. Humans and many mammals are generally dead-end hosts because they develop only low levels of virus in the blood and do not contribute significantly to onward transmission. Transmission routes are primarily mosquito bites, though rare cases have been associated with blood transfusion, organ transplantation, or vertical transmission.

Clinical features and diagnosis

Most infections are subclinical. Symptomatic illness ranges from a self-limited febrile syndrome with fever, headache, and muscle aches to severe neuroinvasive disease such as meningitis, encephalitis, or acute flaccid paralysis. Older adults and people with certain medical conditions are at greater risk for severe outcomes. Diagnosis is commonly by detection of specific antibodies or viral RNA in serum or cerebrospinal fluid; laboratory testing should be interpreted with clinical and epidemiologic context.

Prevention, control, and treatment

There is no specific antiviral therapy that is routinely recommended for WNV; care is mainly supportive. Prevention focuses on reducing mosquito exposure and population control: eliminating standing water where mosquitoes breed, using personal protective measures such as repellents and clothing barriers, and community vector control programs. Vaccines are available for horses but not for general human use, so public health measures and surveillance remain central to limiting spread.

History and geographic spread

WNV was first isolated in 1937 in the West Nile district of Uganda. For decades it was reported intermittently in Africa, parts of Europe, the Middle East, and Asia. Since the 1990s, more frequent outbreaks and wider distribution have been documented. The virus was detected in the Americas at the end of the 20th century and has since established local transmission in multiple regions. Large human outbreaks have occurred at various times and places, highlighting the virus's capacity for rapid geographic expansion.

Public health significance and notable distinctions

West Nile virus is important for veterinary as well as human health; bird mortality can be a sentinel for local transmission and horses may become seriously ill without vaccination. WNV belongs to the same genus as other medically significant viruses (for example, dengue and Zika), but differs in its primary bird–mosquito cycle and clinical patterns. Surveillance, rapid laboratory diagnosis, and integrated vector management are key elements in reducing human and animal disease burden.

Further information and resources

Note: This article summarizes broadly accepted information about West Nile virus. For clinical guidance, diagnosis, or local public health recommendations consult qualified health authorities.